Adicet Bio (ACET)

• Market cap: $78.4M
• 1 day: 1.45%
• 5 days: 5.28%
• 1 month: -5.1%
• 3 months: -0.36%
• 6 months: 19.03%
• Year to date: -4.99%
• 1 year: -19.42%
• 5 years: -92.62%
• 10 years: -99.56%
• Sector: Healthcare
• Industry: Biotechnology

About: Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Employees: 102